Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Karyopharm Trades Up 60% on Positive Phase 3 Multiple Myeloma Results

Karyopharm Therapeutics shares set a new 52-week high price after the company reported that its Phase 3 BOSTON trial of XPOVIO® achieved significant increases in progression-free survival in patients suffering with multiple myeloma. Oncology-focused...
Streetwise Reports | March 3, 2020 |

Next big shale gas boom

Which country has the most shale gas reserves outside of the United States and China? Canada? Nope. Australia? Wrong again. According to the U.S. Energy Information Administration (EIA), Argentina ranks third in recoverable shale gas reserves. Argentina has 774 trill...
Justin Dove | October 28, 2012 |

Two Approvals Underscore Biotech's Pipeline Quality

The green lights and their implications are discussed in an H.C. Wainwright & Co. report. In a Jan. 22 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that the European Commission approved the regimen consisting of Genmab A/S' (GMAB:NASD...
Streetwise Reports | January 30, 2020 |

Several Data Catalysts Expected in 2019 for 'Underappreciated Story'

An H.C. Wainwright & Co. report discussed what those are and why they could impact the biotech's valuation. In a March 18 research note, H.C. Wainwright & Co. analyst Andrew Fein purported that Constellation Pharmaceuticals Inc.'s (CNST:NASDAQ) "strong and balanced pi...
Streetwise Reports | March 25, 2019 |

Immuno-Oncology Firm to Collaborate on Third Clinical Trial with Genentech

Descriptions of the new study and upcoming data readouts for this California-based firm were provided in an H.C. Wainwright & Co. report. In an April 29 research note, H.C. Wainwright & Co. analyst Swayampakula Ramakanth reported that Forty Seven Inc. (FTSV...
Streetwise Reports | May 2, 2019 |

Ardelyx's Shares Soar 65% as Tenapanor Phase 3 Study Hits the Mark

Clinical-stage specialized biopharmaceutical company Ardelyx announced positive results today for its phase 3 AMPLIFY study for tenapanor aimed at improving treatment for cardiorenal diseases. This morning clinical-stage biopharmaceutical developer of medicines for th...
Streetwise Reports | September 4, 2019 |

Avadel Pharma Shares Up 30% Upon Acceleration of Phase 3 REST-ON Study

Avadel Pharmaceuticals' shares are trading 30% higher today on news that the FDA agreed to reduce the sample size required for its Phase 3 REST-ON study, accelerating its completion by year-end 2019. Dublin, Ireland-based Avadel Pharmaceuticals Plc (AVDL:NASDAQ) , wh...
Streetwise Reports | September 24, 2019 |

Phase 2 Data from Potential Multibagger Biopharma 'Checks All the Boxes'

The latest clinical trial results are dissected in a ROTH Capital Partners report. In a Sept. 26 research note, ROTH Capital Partners analyst Jerry Isaacson reported that AzurRx BioPharma Inc.'s (AZRX:NASDAQ) Phase 2 OPTION trial for lead candidate MS1819 in cystic ...
Streetwise Reports | October 1, 2019 |

Dermira's Phase 2b Atopic Dermatitis Trial Results Send Shares 25% Higher

Dermira shares traded higher today after the firm released positive data from its phase 2b study of lebrikizumab in patients with atopic dermatitis at the Las Vegas Fall Clinical Dermatology Conference. Yesterday afternoon, Dermira Inc. (DERM:NASDAQ) , a biopharmaceu...
Streetwise Reports | October 21, 2019 |

NantKwest Shares Jump More than 50% Following JP Morgan Healthcare Conference Presentation

Shares of NantKwest Inc. spiked as much as 85% higher in mid-morning trading setting a new 52-week high price after the company reported a series of positive results at the 38th J.P. Morgan Healthcare Conference in San Francisco. The firm reported that complete responses were ...
Streetwise Reports | January 17, 2020 |
1 2 3 4 5